3.4.21.46: complement factor D
This is an abbreviated version!
For detailed information about complement factor D, go to the full flat file.
Word Map on EC 3.4.21.46
-
3.4.21.46
-
angiogenesis
-
angiogenic
-
vessel
-
metastasis
-
neovascularization
-
hypoxia
-
artery
-
hypoxia-inducible
-
necrosis
-
retinal
-
antiangiogenic
-
umbilical
-
bevacizumab
-
microvessels
-
vein
-
capillary
-
factor-1
-
huvecs
-
vegfr-2
-
collagen
-
vasculature
-
retinopathy
-
eyes
-
ovarian
-
macular
-
tumour
-
tube
-
microvascular
-
mesenchymal
-
anti-vegf
-
lymphatic
-
receptor-2
-
pro-angiogenic
-
bfgf
-
intravitreal
-
progression-free
-
edema
-
choroid
-
metalloproteinase
-
endothelium
-
hypertension
-
sprout
-
matrigel
-
paracrine
-
lymph
-
hif-1alpha
-
mmp-9
-
sunitinib
-
drug development
-
sorafenib
-
vitreous
-
medicine
- 3.4.21.46
- angiogenesis
-
angiogenic
- vessel
- metastasis
- neovascularization
- hypoxia
- artery
-
hypoxia-inducible
- necrosis
- retinal
-
antiangiogenic
-
umbilical
-
bevacizumab
-
microvessels
- vein
- capillary
- factor-1
- huvecs
- vegfr-2
- collagen
- vasculature
- retinopathy
- eyes
- ovarian
-
macular
- tumour
- tube
-
microvascular
- mesenchymal
-
anti-vegf
- lymphatic
- receptor-2
-
pro-angiogenic
- bfgf
-
intravitreal
-
progression-free
- edema
- choroid
- metalloproteinase
- endothelium
- hypertension
-
sprout
- matrigel
-
paracrine
- lymph
- hif-1alpha
- mmp-9
- sunitinib
- drug development
- sorafenib
- vitreous
- medicine
Reaction
selective cleavage of Arg-/-Lys bond in complement factor B when in complex with complement subcomponent C3b or with cobra venom factor =
Synonyms
28 kDa protein, adipocyte, Adipsin, alternative complement pathway component Factor D, C3 convertase activator, C3 proactivator convertase, CFD, complement factor D/adipsin and kallikrein-like serine protease, convertase, C3 proactivator, Df, Df protein, endogenous vascular elastase, esterase, properdin factor D, factor D, factor D (complement), fD, PDGF-D, platelet-derived growth factor D, PoDAK, vascular endothelial growth factor, vascular endothelial growth factor D, VEGF-D
ECTree
Advanced search results
Application
Application on EC 3.4.21.46 - complement factor D
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
-
the enzyme's exosite is a target for design of specific inhibitors for inhibition of the pathway complement activation in advanced dry age-related macular degeneration
drug development
the enzyme's exosite is a target for design of specific inhibitors for inhibition of the pathway complement activation in advanced dry age-related macular degeneration
-
intravitreal VEGF-D gene transfer causes blood-retina barrier breakdown but not neovessel formation in the rabbit eye. Inflammation-like alterations in the choriocapillaries are observed in the baculoviral VEGF-D-treated eyes, but not in adenoviral VEGF-D-treated eyes at 6 days after gene transfer
medicine
-
is linked to the control of lymphangiogenesis and lymphatic metastasis. Epigenetic control of histone acetylation represents an important determinant of vegf-D gene expression in cancer cells
medicine
-
PDGF-D is present in the neointima of the arteriopathy of chronic allograft nephropathy, where it can engage PDGF-Rbeta to promote mesenchymal cell migration, proliferation, and neointima formation. PDGF-D may engage the PDGF-Rbeta to promote interstitial injury in chronic allograft injury
medicine
VEGF-D plays an essential role in tumoral lymphangiogenesis and lymphatic spread, VEGF-D expression, and the intratumoral lymphatics may be clinically useful indicators for prognostic evaluation in patients with epithelial ovarian carcinoma
medicine
-
by downregulation of VEGF-D expression in a lung tumor mouse model using Deguielin, a rotenoid of the flavonoid family, tumor-associated lymphangiogenesis and lymphatic metastasis are suppressed
medicine
-
serum VEGF-D levels are a good biomarker for lymphatic involvement in patients with lympangioleiomyomatosis